A New Approach to Ventilator-associated Pneumonia Based on the PIRO System

I. Martin-Loeches, M. Ulldemolins, and E. Diaz

Introduction

Several new scoring systems have been developed over recent years to assess the degree of organ failure (e.g., Acute Physiology and Chronic Health Evaluation [APACHE] II, APACHE III, Sequential Organ Failure Assessment [SOFA], Simplified Acute Physiology Score [SAPS] II, and Multiple Organ Dysfunction Score [MODS]). Most of these were models generated based on the concepts of sepsis, severe sepsis and septic shock. In 2001, an International Sepsis Definition Conference updated these terms in order to facilitate standardized enrolment into clinical trials, but due to their simplicity and easy use physicians rapidly adopted them for daily clinical practice [1].

However, few of these scoring systems are focused on ventilator-associated pneumonia (VAP), the leading cause of nosocomial infection in critically ill patients requiring mechanical ventilation [2]. The approach to VAP severity has been traditionally based on three clinical items: The underlying disease, the time of onset, and the causative microorganism. The VAP-PIRO score (Table 1) [3], based on the PIRO system (predisposition, insult, response, organ dysfunction), has been recently developed by our group and endeavors to identify different risk levels for VAP. This score stratifies patients with VAP into mortality risk groups and correlates these with health-care resource use in VAP patients. The PIRO concept, a conceptual framework for understanding sepsis [1], is a classification scheme that could stratify patients based on their predisposing conditions, the nature and extent of the insult, the nature and magnitude of the host response, and the degree of the concomitant organ dysfunction. Conceptually, PIRO was

Table 1. Summary of the main components of the VAP-PIRO scoring system

| P | I | R | O |
|---|---|---|---|
| COPD | Bacteremia | Clinical resolution | Renal failure |
| Immunocompromised host | Pathogens | Biomarkers | ARDS |
| Trauma patient | MRSA | Compartimentalization | VAT |
| Genetic factors | Pseudomonas spp. | Shock | Blood transfusions |
| | Aanetobacter spp. | Immunoparalysis, macrolides | |
| | Candida spp. | | |

VAT: ventilator-associated tracheobronchitis; ARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; MRSA: methicillin-resistant *Staphylococcus aureus*
modeled on the TNM (tumor, nodes, metastases) classification [4] which has been successfully used to define prognostic indicators in clinical oncology. PIRO was introduced as a hypothesis-generating model for future research, but its practical applications were limited. The aim of this chapter is to describe a new approach to the prognosis of VAP based on the PIRO concept focusing in its main components and their relative impact on VAP severity and prognosis.

Figure 1 shows the mortality rate in ICU patients with VAP classified according to the VAP-PIRO score.

Components of the VAP-PIRO Score: Predisposition

Genetic Factors

Despite considerable advances in our understanding of the biology of pneumonia, improvements in clinical outcomes have been sporadic and, with few notable exceptions, because of improvements in supportive care rather than specific therapies. As a result, morbidity, mortality, and costs remain high.

Although it is clear that gene sequencing and manipulation of experimental models have provided a better approach for insight into the biology of the inflammatory response to infection, these technologies and their application to the study of naturally occurring human genetic variation have yet to provide the same insight or clinical benefit. Variations in genes encoding important components of the inflammatory response and the microbial recognition system are likely to be involved in the development of pneumonia. In contrast to entities such as community-acquired pneumonia (CAP) or meningitis where ‘the genetic approach’ is being developed with some success, there are still scarce data that link VAP to genetic variability [5–9].

In addition, genetics may explain the wide variation in the individual response to infection that has puzzled clinicians for long. VAP phenotypes can range from septic shock to a very well compartmentalized consolidation on x-ray accompanied by low grade hypoxemia. Fortunately, novel therapeutic strategies are currently being developed in experimental models to modulate the inflammatory response in the host and may be available at the bedside in the near future.
Underlying Diseases

Chronic obstructive pulmonary disease (COPD) is a risk factor for nosocomial lower respiratory tract infections. The incidence of VAP in intubated COPD patients has been estimated to range between 6 and 33% [10]. Tracheo-bronchial colonization, local and systemic immunosuppression and frequent antibiotic treatment are factors predisposing to VAP in these patients. However, the impact of COPD on VAP mortality remains controversial. Our group [11] demonstrated that COPD was associated with higher mortality rates in patients with VAP. However, after adjustment for confounding factors, COPD was not independently associated with mortality in these patients. In contrast, Nseir et al. [12] reported that VAP was associated with higher mortality rates and longer duration of mechanical ventilation and intensive care unit (ICU) stay in COPD patients, and was independently associated with ICU mortality.

Immunocompromised host

A huge number of immunocompromised patients are admitted to the ICU and immunosuppression has been recognized as an independent risk factor for infectious morbidity and mortality [13]. In addition, immunosuppression represents a risk factor for multidrug-resistant pathogens in VAP and should be considered in treatment decisions. As has been described by Nseir et al. [12], a significantly greater proportion of immunosuppressed patients received antibiotic therapy before and during ICU admission, being more likely to be colonized and/or infected by multidrug resistant organisms. However, despite the evidence available, current guidelines for treatment of VAP and or hospital-acquired pneumonia (HAP)/VAP do not consider patients who are known to be immunosuppressed because of human immunodeficiency virus (HIV) infection, hematologic malignancy, chemotherapy-induced neutropenia or organ transplantation [14], factors likely to determine prognosis.

Trauma patients

Trauma deaths have a classic trimodal distribution. Late death (3 days to 3 weeks postinjury) occurs in more than 25% of the patients, in whom infection is the principal cause of death and is associated with high rates of extracranial complications, like pneumonia, that determine the final outcome. In fact, Bronchard et al. [15], in trauma patients, described that for patients developing pneumonia there was a higher risk of secondary cerebral injury, increased intra-cranial pressure, hypotension, fever and hypoxemia that would worsen outcomes in such patients. Therefore, in trauma patients, early identification of subjects at a high risk of developing VAP reduces morbidity and costs.

Trauma patients exhibit greater incidences of early-onset VAP, which accounts for 30–40% of cases [15]. Most reports regarding microorganisms indicate that methicillin-sensitive Staphylococcus aureus (MSSA) is the predominant pathogen in multiple-trauma patients in coma, and nasal MSSA colonization at the time of severe injury may increase the risk of MSSA pneumonia [16]. As length of stay increases, causal pathogens are likely to switch to antibiotic-resistant bacteria. Rangel et al. [17] reported that the presence of multi-drug resistance (Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, and methicillin-resistant S. aureus [MRSA]) in respiratory isolates increased from
27% to 52% after 5 days of admission. Therefore, in comatose patients, coverage with a beta-lactam active against MSSA is mandatory when early VAP is suspected, however treatment of late onset VAP should be based on local bacteriologic patterns and antimicrobial susceptibility.

**Components of the VAP-PIRO Score: Insult**

**Bacteremia**

In HAP, bacteremia occurs in 8 to 20% of the episodes [18] and is associated with high mortality rates [19], but because many of these studies were not designed to investigate attributable mortality, little is known regarding its real impact on VAP patients. Agbaht et al. [20] found that bacteremic-VAP was independently associated with increased ICU mortality. Moreover bacteremic episodes occurred later during the ICU stay and were more frequent in previously hospitalized patients. MRSA was found to be an independent risk factor for bacteremia and Depuydt et al. [21] reported a high mortality rate in MRSA bacteremia associated with nosocomial pneumonia.

**Pathogens**

Consideration of the particularities of each ICU’s ecology should provide a more rational basis for selecting initial therapy for VAP patients before culture results are available. As we reported [22], the observed differences in pathogen etiology across institutions reflected differences in antibiotic use and local patterns of resistance, which prompted the development of a more patient specific antibiotic management.

The impact of multidrug resistant pathogens, including *P. aeruginosa* and MRSA, causing nosocomial infection is ever-increasing and is now recognized as a major health problem. Multidrug resistant pathogens have been recognized as contributing to unfavorable clinical outcome and increased resource utilization [23]. The greater associated hospital mortality has been attributed to the virulence of these bacteria and the increased occurrence of inadequate initial antibiotic treatment of VAP due to the presence of antibiotic resistance. However, the impact of multidrug resistance is difficult to assess because of the presence of multiple patient characteristics that may confound uniform analysis.

*P. aeruginosa*, MRSA and *A. baumannii* represent the three most important microorganisms in VAP.

**Pseudomonas aeruginosa**

*P. aeruginosa* represents the most prevalent microorganism in VAP in different series and is associated with high mortality rates [24]. Some surface factors, by either injecting cytotoxin to damaged epithelial cells or by rupturing epithelial integrity or by mechanisms like the type III secretion system, increase *P. aeruginosa*’s virulence, particularly exoU. The type III secretion system induces the translocation of toxins from the bacterial cytoplasm into the cytosol of host cells directly. *P. aeruginosa* strains producing type III secreted proteins are linked with worse outcome [25].

Zhuo et al. [26] reported that patients with large burdens of *P. aeruginosa* had an increased risk of death and possessed more virulent strains. Therefore, a high
burden of \( P. \) *aeruginosa* may be a marker of inadequate host defense and its presence may also further compromise target host immune cells, for example, macrophages and neutrophils, allowing organisms to evade the immune response and often reducing the number of viable host defense cells.

**Staphylococcus aureus**

*S. aureus* is the most important Gram-positive pathogen in VAP. In the recent European multicenter study [27], EUVAP, the most common isolate was *S. aureus* in 32.3% of cases; 16.3% were MSSA and 16.0% MRSA. Virulence and therapy-related factors, such as inappropriate antibiotic prescription, have been consistently associated with increased mortality. There are several factors linked with MRSA isolation in VAP episodes: Administration of antibiotics before the development of VAP [28] and length of hospital stay, rather than the period of mechanical ventilation, were strongly associated with MRSA isolation [29]. Vidaur et al. [30] found that MRSA VAP treated with appropriate therapy resolved more slowly than VAP due to *Haemophilus influenzae*, MSSA, and *P. aeruginosa* treated with appropriate therapy. The risk of death in MRSA episodes is 20 times higher than in episodes caused by MSSA strains treated with beta-lactams [31] and a recent report showed that MRSA-VAP episodes were independently associated with prolonged hospitalization and higher costs than MSSA VAP episodes, even when therapy was appropriate [32].

**Acinetobacter baumannii**

Several studies have investigated the attributable mortality of *A. baumannii* and found controversial results. Fagon et al. [33] reported higher mortality in cases with VAP caused by *A. baumannii* and *P. aeruginosa* than in controls with bronchial colonization. In contrast, Garnacho-Montero et al. [34], found that VAP due to *A. baumannii* was not associated with worse outcomes than other causes of VAP in a matched case-control study. *A. baumannii* exhibits intrinsic resistance to multiple antimicrobial agents and generates continuing controversy about whether VAP caused by this microorganism increases morbidity and mortality independently of the effects of other confounding factors in ICU setting.

**Candida species**

In immunocompetent mechanically ventilated patients, isolation of *Candida* spp. from the respiratory tract is relatively common. Olaechea et al. [35] found an association with *Candida* spp. isolation and longer ICU and hospital stays and resource utilization. Azoulay et al. [36] reported that *Candida* spp. colonization was associated with an increased risk of *P. aeruginosa* VAP. *Candida* spp. and *P. aeruginosa* were among the most common microorganisms retrieved from endotracheal tube biofilm and tracheal secretions in patients with VAP. This can be explained because both microorganisms have identical functional enzymes, such as 2’ phosphotransferase, acting in concert with ligase to splice transfer RNA molecules. Preemptive treatment with local or systemic therapy has been proposed in order to reduce the incidence of *P. aeruginosa* VAP [37].

**Ventilator-associated Tracheobronchitis (VAT) as an Intermediate Insult for VAP**

VAT might represent an intermediate process between colonization and VAP [38] and probably is a continuum between bronchitis and pneumonia in mechanically
ventilated patients. Host defenses can be overwhelmed by a large aspirated inoculum or an inherently virulent organism and the main reason for developing infection in the upper airways is the imbalance between host defenses and excess of mucus. Recent studies have shown that bronchial/tracheal epithelial cells are functionally different and represent a first step of injury [39]. VAT represents an interesting target for treatment since it may prevent the progression to VAP, shorten the use of antibiotics that reduce cost and minimize the selective pressure on ICU ecology [40].

**Blood Transfusion**

The majority of critically ill patients require a transfusion of packed red blood cells (RBCs) at some point during their ICU stay. The incidence of blood transfusion during the ICU stay has been reported to be as frequent as 37.0 % [42]. Nevertheless, transfusion of packed RBCs is not without risk since it represents an insult to the host’s immune system with enhancement of cytokine response. Anti-inflammatory (interleukin [IL]-10) and pleiotropic (IL-6) cytokines are increased during transfusion of packed RBCs. Blood transfusion has been associated with nosocomial infection-like surgical site infections and potentiates the risk for catheter-related bloodstream infection but also increases the risk of developing VAP.

Shorr et al. [42] reported that transfusion was independently associated with an increased risk for VAP, the effect of transfusion on late-onset VAP being more pronounced and dose-response dependent. Therefore, blood transfusion needs to be considered cautiously in critical care patients in order to evaluate potential adverse events and to acknowledge that the burden of proof is shifting to suggest that transfusion avoidance may be the safer paradigm [43].

**Components of the VAP-PIRO Score: Response**

**Clinical Resolution**

Early clinical recognition of therapeutic failure is of paramount importance if corrective measures are to be taken. While this will intuitively make sense to clinicians, data available on this issue are very limited. Several studies have suggested that improvement in oxygenation is the most reliable criteria to distinguish patients who are responding to antibiotic treatment from those who are not. Luna et al. [44] evaluated the performance of the Clinical Pulmonary Infection Score (CPIS) in identifying which patients with VAP respond to therapy. These authors discovered that only the PaO$_2$/FiO$_2$ ratio could distinguish survivors from non-survivors, as early as day 3 of therapy for VAP. Moreover they reported that the PaO$_2$/FiO$_2$ ratio improved above 250 mmHg in survivors, and this improvement happened before improvement in the other components of the score (white blood cell count, fever, secretions, and radiographic abnormalities). Thus, the PaO$_2$/FiO$_2$ ratio may represent a very accurate and rapid measure of the patient’s response to therapy and can help tailor appropriate duration of therapy. However, Vidaur et al. [45] reported that improvement in oxygenation was unreliable in patients with the acute respiratory distress syndrome (ARDS), and only fever was delayed compared with non-ARDS patients. At days 7–8 of treatment, when antibiotics for VAP are commonly discontinued [46], Chastre et al. reported that more than 35 % of ARDS patients with VAP remain febrile.
Clinical patterns, such as fever and hypoxemia, are clinical variables that can be easily followed at the bedside of the patient simply by physical examination to monitor clinical response and to individualize and shorten the duration of antibiotic therapy.

**Use of Biomarkers to Quantify the Response to VAP**

Several biomarkers have been proposed as the most promising candidates, such as leukocyte count, C-reactive protein (CRP) and procalcitonin (PCT), for correlating with the prognosis of VAP [47]. Seligman et al. [48] reported that decreases in either serum PCT or CRP levels between onset and the fourth day of treatment could predict survival of VAP patients. Similarly, Luyt et al. [49] reported different procalcitonin levels as strong predictors of unfavorable outcome (death, recurrent VAP or development of extrapulmonary infection) by a point-of-care test at days 1, 3 and 7 in patients with VAP. However, neither PCT nor CRP threshold values nor their kinetics could predict the development of septic shock in VAP patients [50].

Recently, other biomarkers such as midregional pro-atrial natriuretic peptide (MR-proANP) and copeptin have been suggested and tested as prognostic markers, but their function in VAP resolution is still unproven [51, 52].

**Compartmentalization**

The response to VAP may vary from compartmentalized forms that account for a local response with minor systemic compromise to systemic spillover or escape of inflammation leading to septic shock and uninfected multiorgan failure.

Cytokines are the key factors in the pathogenesis of pneumonia and add complexity of signaling during VAP development. Millo et al. [53] reported that the production of cytokines and cytokine inhibitors was compartmentalized within the lungs in patients who developed VAP. They reported a significant increase in concentration of tumor necrosis factor (TNF)-α, soluble TNF-α receptors [sTNFaRI], IL-1α, and IL-1β in non-directed bronchoalveolar lavage (BAL) fluid.

Similarly, VAP is characterized by a shift in the local hemostatic balance to the procoagulant side, which precedes the clinical diagnosis of VAP. Fibrin deposits enhance inflammatory responses by increasing vascular permeability, activating endothelial cells to produce pro-inflammatory mediators, and eliciting recruitment and activation of neutrophils; eventually, these effects will disrupt normal gas exchange by creating intrapulmonary shunts and ventilation-perfusion mismatches.

As has been reported by Schultz et al. [54], patients with VAP, before the clinical manifestation, had a dramatic increase in procoagulant activity, increased BAL levels of thrombin-antithrombin III complex (TAT), and decreased fibrinolysis, as reflected by a gradual fall in BAL levels of plasminogen activator activity.

**Shock**

The inflammatory response of the host to an infection is associated with increased circulating levels of pro-inflammatory cytokines, such as IL-6 and IL-8. The clinical presentation of VAP varies widely, from a relatively benign illness to
a devastating illness resulting in septic shock. The incidence of septic shock among VAP patients can be as high as 50% in reported series [48]. Bonten et al. [55] reported that high circulating levels of IL-6 and IL-8 were associated with higher mortality rates and with a clinical presentation of severe sepsis or septic shock. Moreover soluble triggering receptor expressed on myeloid cells (sTREM)-1 is particularly increased on evolution from sepsis or severe sepsis to septic shock in patients with VAP. Its sustained increase might be an indicator for poor outcome [56].

Our group reported that septic shock was an independent variable associated with ICU mortality (OR 4.40 CI 2.71–7.15) [3]. The early stages of VAP may be accompanied by circulatory insufficiency resulting from hypovolemia, myocardial depression, increased metabolic rate, and vasoregulatory perfusion abnormalities. As a consequence, a variety of hemodynamic combinations create a systemic imbalance between tissue oxygen supply and demand, leading to global tissue hypoxia and shock. Early correction of septic shock is crucial for patient outcomes, for which reason consensus guidelines now recommend early goal-directed therapy [57] for the first six hours of sepsis resuscitation.

**Immunoparalysis**

In the past, immodulatory therapies in sepsis were driven by the assumption that the adverse outcomes were related to an overly exuberant inflammatory response. However, over the last few years, new evidence on cytokine production in response to bacterial antigens, lymphocyte proliferation in response to recall antigens, or new antigen presentation as a marker of immune function has been released. For example, low HLA-DR expression has been correlated with the development of nosocomial infections, and persistence of abnormally low levels of HLA-DR in the late phase of septic shock (day 5–7) has been linked to death [58]. New studies based on HLA-DR modulation in patients with VAP might improve the understanding of the response to VAP.

**Immunomodulatory Effects of Macrolides**

Compelling evidence has shown that appropriate antibiotic therapy is the cornerstone of success in the treatment of patients with VAP [59]. However, despite early diagnosis and prompt initiation of antibiotics, mortality remains high in severe sepsis [60]. Recent studies suggest that macrolides may have beneficial effects for patients at risk of certain infections due to their immunomodulatory effects rather than their antimicrobial properties [61]. Based on favorable results in experimental models of sepsis caused by Gram-negative organisms, Giamarellos-Bourboulis et al. [62] conducted a randomized controlled trial (RCT) in 200 patients with VAP who were randomly assigned to receive either placebo or clarithromycin. They showed that despite no differences in 28-day mortality rates between the two groups, clarithromycin accelerated the resolution of VAP and weaning from mechanical ventilation in surviving patients and delayed death in those who died of sepsis. The explanation can be based on the regulation of leukocyte function and production of inflammatory mediators, control of mucus hypersecretion, resolution of inflammation, and modulation of host defense mechanisms or on bacterial quorum sensing in *P. aeruginosa* infections. Moreover, some evidence suggests that macrolides might facilitate the killing of micro-
organisms in acute respiratory infections through the stimulation of neutrophil activation, whereas blood monocytes release lower amounts of TNF-α without any change in tissue bacterial load [63].

**Components of the VAP-PIRO Score: Organ Dysfunction**

**Renal Failure**

VAP is a risk factor for the development of acute renal failure. The incidence of acute renal failure for the population at risk has been reported to be around 38% [64]. In this study, VAP caused by multidrug resistant pathogens and sepsis were independent risk factors for the development of acute renal failure. However, there is not yet enough evidence in the published data to explain the relationship between multidrug resistant infections and the development of acute renal failure.

**Acute Respiratory Distress Syndrome**

Nosocomial pneumonia is a frequent complication of ARDS and *vice versa*. Epidemiologic studies have reported that VAP was present in 20–75% of patients dying of ARDS [65]. Fibrin deposition within the air space is one of the hallmarks of ARDS. Alveolar fibrin deposits appear to contribute to the magnitude of the inflammatory response by virtue of the ability of their cleavage and degradation products to promote chemotaxis, to increase vascular permeability, and to exert modulatory effects on various immune cells. In addition, fibrin may participate in the resolution phase of ARDS, possibly contributing to lung fibrosis by providing a matrix for macrophage migration and by promoting angiogenesis and collagen deposition [66].

**Conclusion**

Despite recent advances in VAP management, VAP cannot yet be prevented. Some risk factors for developing VAP are not modifiable and the etiology of each episode varies markedly according to the time to pneumonia onset and underlying diseases in the host. The VAP-PIRO approach takes into account these risk factors and the consideration of predisposing conditions, the nature and extent of insult, the nature and magnitude of the host response; in addition, the degree of concomitant organ dysfunction provides a useful and novel approach to VAP. The VAP-PIRO approach may improve the understanding of the natural history and the stratification of patients according to severity of each VAP episode. VAP-PIRO could be useful both for benchmarking and for balancing sickness severity in future randomized clinical trials.

**Acknowledgments:** The authors thank Dr. Jordi Rello, from the Vall d’Hebron University Hospital, Barcelona (Spain), for his critical review and useful insights for this paper.
References

1. Levy MM, Fink MP, Marshall JC, et al (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31: 1250 – 1256
2. American Thoracic Society and Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and health-care-associated pneumonia. Am J Respir Crit Care Med 171: 388 – 416
3. Lisboa T, Díaz E, Sa-Borges M, et al (2008) The ventilator-associated pneumonia PIRO score: a tool for predicting ICU mortality and health-care resources use in ventilator-associated pneumonia. Chest 134: 1208 – 1216
4. Sellers A (1960) The staging of breast cancer, trial of the TNM method. Can J Surg 4: 116 – 117
5. Waterer GW, Quasney MW, Cantor RM, Wunderink RG (2001) Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Resp Crit Care Med 163: 1599 – 1604
6. Gallagher PM, Lowe G, Fitzgerald T, et al (2003) Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 58: 154 – 156
7. Wattanatham A, Manocha S, Groshau HS, Russel JAI, Walley KR (2005) Interleukin-10 haplotype associated with increased mortality in critically ill patients with sepsis from pneumonia but not in patients with extrapulmonary sepsis. Chest 128: 1690 – 1698
8. Brouwer MC, de Gans J, Heckenberg SG, Zwinderman AH, van der Poll T, van de Beek D (2009) Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect Dis 9: 31 – 44
9. Texereau J, Chiche JD, Taylor W, Choukroun G, Comba B, Mira JP (2005) The importance of Toll-like receptor 2 polymorphisms in severe infections. Clin Infect Dis 41 (Suppl 7): S408 – 415
10. Rello J, Rodriguez A, Torres A, et al (2006) Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 27: 1210 – 1216
11. Rello, J, Ausina, V , Ricart, M, et al (1993) Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 104: 1230 – 1235
12. Neisr S, Di Pompeo C, Soubrier S, et al (2005) Impact of ventilator-associated pneumonia on outcome in patients with COPD. Chest 128: 1650 – 1656
13. Ibrahim EH, Tracy L, Hill C, Fraser VJ, Kollef MH (2001) The occurrence of ventilator-associated pneumonia in a community hospital: risk factors and clinical outcomes Chest 120: 555 – 561
14. Torres A, Ewig S, Lode H, Carlet J (2009) Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med 35: 9 – 29
15. Bronchard R, Albalaedjo P, Brezac G, et al (2004) Early onset pneumonia: risk factors and consequences in head trauma patients. Anesthesiology 100: 234 – 239
16. Sirgo G, Bodí M, Díaz E, Rello J (2002) Pneumonia in head-injured and severe trauma patients.. Semin Respir Crit Care Med 23: 435 – 441
17. Rangel EL, Butler KL, Johannigman JA, Tsuei BJ, Solomkin JS (2009) Risk factors for relapse of ventilator-associated pneumonia in trauma patients. J Trauma 67: 91 – 95
18. Taylor GD, Buchanan-Chell M, Kirkland T, et al (1995) Bacteremic nosocomial pneumonia. A 7-year experience in one institution. Chest 108: 786 – 788
19. DeRyke CA, Lodise TP Jr, Rybak MJ, et al (2005) Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest 128: 1414 – 1422
20. Agbaht K, Díaz E, Muñoz E, et al (2007) Bacteremia in patients with ventilator-associated pneumonia is associated with increased mortality: a study comparing bacteremic vs non-bacteremic ventilator associated pneumonia. Crit Care Med 35: 2064 – 2070
21. Depuydt P, Benoit D, Vogelaers D, et al (2006) Outcome in bacteremia associated with nosocomial pneumonia and the impact of pathogen prediction by tracheal surveillance cultures Intensive Care Med 32: 1773 – 1781
22. Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J (1999) Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 160: 608 – 613
23. Depuydt PO, Vandijck DM, Bekaert MA, et al (2008) Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia. Crit Care 12: R142
24. Rello J, Jubert P, Vallés J, Artigas A, Rué M, Niederman MS (1996) Evaluation of outcome for intubated patients with pneumonia due to P aeruginosa aeruginosa. Clin Infect Dis 23: 973–978
25. Roy-Burman A, Savel RH, Racine S, et al (2001) Type III protein secretion is associated with death in lower respiratory and systemic P aeruginosa aeruginosa infections. J Infect Dis 183: 1767–1774
26. Zhuo H, Yang K, Lynch SV, et al (2008) Increased mortality of ventilated patients with endotracheal P aeruginosa aeruginosa without clinical signs of infection Crit Care Med 36: 2495 – 2503
27. Koulenti D, Lisboa T, Brun-Buisson C, et al (2009) Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care. Crit Care Med 37: 2360–2368
28. Trouillet J, Chastre J, Vuagnat A, et al (1998) Ventilator- associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157: 531 – 539
29. Ibrahim EH, Ward S, Sherman G, et al (2000) A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest 117: 1434–1442
30. Vidaur L, Planas K, Sierra R, et al (2008) Ventilator-associated pneumonia: impact of organisms on clinical resolution and medical resources utilization. Chest 133: 625–632
31. Rello J, Torres A, Ricart M, et al (1994) Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 150: 1545–1549
32. Shorr AF, Tabak YP, Gupta V, et al (2006) Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care 10: R97
33. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C (1993) Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 94: 281–288
34. Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J (2003) Clinical impact of pneumonia caused by A A baumannii baumannii in intubated patients: a matched cohort study. Crit Care Med 31: 2478–2482
35. Olaechea PM, Palomar M, León-Gil C, et al (2004) Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 23: 323–330
36. Azoulay E, Timsit JF; Tafflet M, et al (2006) Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest 129: 110–117
37. Nseir S, Jozefowicz E, Cavestri B, et al (2007) Impact of antifungal treatment on Candida-Pseudomonas interaction: a preliminary retrospective case-control study. Intensive Care Med 33: 137–142
38. Craven DE, Chroneou A, Zias N, Hjalmarsen KI (2009) Ventilator-associated tracheobronchitis: the impact of targeted antibiotic therapy on patient outcomes. Chest 135: 521–528
39. Seki N, Shirasaki H, Kikuchi M, Himi T (2007) Capsaicin induces the production of IL-6 in human upper respiratory epithelial cells. Life Sci 80: 1592–1597
40. Martin-Loeches I, Pobo A (2010) What’s new in ventilator-associated tracheobronchitis. Clin Pulm Med 17: 117–121
41. Vincent JL, Sakr Y, Sprung C, et al (2008) Are blood transfusions associated with greater mortality rates? Results of the Sepsis Occurrence in Acutely Ill Patients study. Anesthesiology 108: 31–39
42. Shorr AF, Duh MS, Kelly KM, Kollef MH; CRIT Study Group (2004) Red blood cell transfusion and ventilator-associated pneumonia: A potential link? Crit Care Med 32: 666–674
43. Zilberberg MD, Carter C, Lefebvre P, et al (2007) Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study. Crit Care 11: R63
44. Luna CM, Blanzaco D, Niederman MS, et al (2003) Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 31: 676–682
45. Vidaur L, Gualis B, Rodriguez A, et al (2005) Clinical resolution in patients with suspicion of ventilator-associated pneumonia: A cohort study comparing patients with and without acute respiratory distress syndrome. Crit Care Med 33: 1248–1253
46. Chastre J, Wolff M, Fagon JY, et al (2003) Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA 290: 2588–2598
47. Boucher BA, Hanes SD (1999) Searching for simple outcome markers in sepsis: an effort in futility? Crit Care Med 27: 1390–1391
48. Seligman R, Meisner M, Lisboa TC, et al (2006) Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care 10: R125
49. Luyt CE, Guerin V, Combes A, et al (2005) Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 171: 48–53
50. Hillas G, Vassilakopoulos T, Plantza P, Rasidakis A, Bakakos P (2010) C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia. Eur Respir J 35: 805–811
51. Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJ (2008) Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. Crit Care 12: R11
52. Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJ (2008) Prognostic value of midregional pro-atrial natriuretic peptide in ventilator-associated pneumonia. Intensive Care Med 34: 2084–2091
53. Millo JL, Schultz MJ, Williams C, et al (2004) Compartmentalisation of cytokines and cytokine inhibitors in ventilator-associated pneumonia. Intensive Care Med 30: 68–74
54. Schultz MJ, Millo J, Levi M, et al (2004) Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 59: 130–135
55. Bonten MJ, Froon AH, Gaillard CA, et al (1997) The systemic inflammatory response in the development of ventilator-associated pneumonia. Am J Respir Crit Care Med 156: 1105–1113
56. Routsi C, Giamarellos-Bourboulis EJ, Antonopoulou A, et al (2005) Does soluble triggering receptor expressed on myeloid cells-1 play any role in the pathogenesis of septic shock? Clin Exp Immunol 142: 62–67
57. Rivers E, Nguyen B, Hlavst S, et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345: 1368–1377
58. Finck ME, Elmenkouri N, Debard AL, et al (2003) Preliminary results in standardization of flow cytometry protocols for monocytic HLA-DR measurement and their application in the follow up of septic shock. Ann Biol Clin 61: 441–448
59. Clec'h C, Timsit JF, De Lassence A, et al (2004) Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. Intensive Care Med 30: 1327–1333
60. Dellinger RP, Levy MM, Carlet JM et al (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36: 296–327
61. Parnham MJ (2005) Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 18: 125–131
62. Giamarellos-Bourboulis EJ, Tziortzioti V, Koutoukas P, et al (2006) Clarithromycin is an effective immunomodulator in experimental pylonephritis caused by pan-resistant Klebsiella pneumoniae. J Antimicrob Chemother 57: 973–944
63. Giamarellos-Bourboulis EJ (2008) Immunomodulatory therapies for sepsis: unexpected effects with macrolides. Int J Antimicrob Agents 32 (Suppl 1): S39–43
64. Gursel G, Aydogdu M, Ozyilmaz E, Ozis TN (2008) Risk factors for treatment failure in patients with ventilator-associated pneumonia receiving appropriate antibiotic therapy. J Crit Care 23: 34–40
65. Markowicz P, Wolff M, Djeda¨i ni K, et al (2000) Multicenter prospective study of ventilator-associated pneumonia during acute respiratory distress syndrome. Incidence, prognosis, and risk factors. ARDS Study Group. Am J Respir Crit Care Med 161: 1942–1948
66. Bastarache JA, Fremont RD, Kropski JA, Bossert FR, Ware LB (2009) Procoagulant alveolar microparticles in the lungs of patients with acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 297: L1035–1041